# Novartis Vaccines clinical trials: 165 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 165 trials with Novartis Vaccines as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Novartis Vaccines: 165 rows for $8.25, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/novartis-vaccines

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 165
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 165, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 3, 2014 | NCT02256488 | Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects | Novartis Vaccines | Phase 3 | Completed | Prophylaxis: Influenza | 1,561 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02256488) |
| October 2, 2014 | NCT02255279 | Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to \<72 Months of Age in Mexico. | Novartis Vaccines | Phase 3 | Completed | Influenza | 287 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02255279) |
| May 16, 2014 | NCT02140762 | Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents | Novartis Vaccines | Phase 2 | Completed | Meningococcal Disease | 305 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02140762) |
| May 15, 2014 | NCT02139228 | Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children | Novartis Vaccines | Phase 3 | Completed | Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b | 426 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02139228) |
| November 29, 2013 | NCT01998477 | A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to \<18 Years of Age at Risk for Influenza-Related... | Novartis Vaccines | Phase 3 | Completed | Influenza | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01998477) |
| November 26, 2013 | NCT01994629 | Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT... | Novartis Vaccines | Phase 2 | Completed | Meningococcal Disease | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01994629) |
| November 25, 2013 | NCT01992536 | Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a... | Novartis Vaccines | Phase 2 | Completed | Meningococcal Disease | 194 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01992536) |
| November 25, 2013 | NCT01992107 | Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old | Novartis Vaccines | Phase 3 | Completed | Influenza | 2,333 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01992107) |
| November 25, 2013 | NCT01992094 | Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older | Novartis Vaccines | Phase 3 | Completed | Influenza | 2,680 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01992094) |
| October 31, 2013 | NCT01973218 | Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years. | Novartis Vaccines | Phase 3 | Completed | Meningococcal Disease | 264 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01973218) |
| September 2, 2013 | NCT01933646 | Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China | Novartis Vaccines | Observational | Completed | Invasive Group B Streptococcal Disease | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01933646) |
| August 26, 2013 | NCT01928472 | Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years | Novartis Vaccines | Phase 1 | Completed | H7N9 Influenza | 402 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01928472) |
| July 30, 2013 | NCT01911221 | A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When... | Novartis Vaccines | Phase 3 | Completed | Prevention of the Meningococcal Disease | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01911221) |
| July 10, 2013 | NCT01894919 | Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination... | Novartis Vaccines | Phase 3 | Completed | Meningoccocal Disease, Meningococcal Meningitis | 851 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01894919) |
| June 24, 2013 | NCT01885117 | Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg... | Novartis Vaccines | Phase 3 | Completed | Human Influenza | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01885117) |
| June 19, 2013 | NCT01880697 | Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above | Novartis Vaccines | Phase 3 | Completed | Human Influenza | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01880697) |
| June 18, 2013 | NCT01879553 | Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18... | Novartis Vaccines | Phase 2 | Completed | Human Influenza | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01879553) |
| June 18, 2013 | NCT01879540 | Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant... | Novartis Vaccines | Phase 2 | Completed | Human Influenza | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01879540) |
| May 20, 2013 | NCT01857206 | Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age | Novartis Vaccines | Phase 3 | Completed | Influenza, Fever | 2,055 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01857206) |
| May 17, 2013 | NCT01855945 | Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to \<9 Years, Adolescents 9 to \<18 Years... | Novartis Vaccines | Phase 1 | Completed | Prophylaxis of A/H3N2v Influenza | 627 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01855945) |
| April 4, 2013 | NCT01823536 | Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose | Novartis Vaccines | Phase 4 | Completed | Meningococcal Disease | 465 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01823536) |
| January 28, 2013 | NCT01776554 | Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children | Novartis Vaccines | Phase 2 | Completed | Pandemic H5N1 Influenza | 662 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01776554) |
| January 28, 2013 | NCT01776541 | Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults | Novartis Vaccines | Phase 2 | Completed | Pandemic H5N1 Influenza | 979 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01776541) |
| January 11, 2013 | NCT01766921 | Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects | Novartis Vaccines | Phase 2 | Completed | Pandemic H5N1 Influenza | 1,393 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01766921) |
| November 27, 2012 | NCT01734434 | Study to Identify Factors Influencing Access of Pregnant Women and Their Infants to Local Healthcare Systems | Novartis Vaccines | Observational | Completed | Pregnancy, Newborn Health | 3,243 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01734434) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 1/2 | 1 |
| Phase 2 | 55 |
| Phase 2/3 | 7 |
| Phase 3 | 70 |
| Phase 4 | 10 |
| Observational | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 163 |
| Withdrawn | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Influenza, Human | 59 |
| Meningococcal Infections | 44 |
| Meningitis, Meningococcal | 27 |
| Meningitis | 24 |
| Influenza in Birds | 8 |
| Haemophilus Infections | 8 |
| Rabies | 6 |
| Orthomyxoviridae Infections | 4 |
| Guillain-Barre Syndrome | 4 |
| Disease | 4 |
| Infections | 4 |
| Whooping Cough | 3 |
| Tetanus | 3 |
| Diphtheria | 2 |
| Streptococcal Infections | 2 |
| Hepatitis B | 2 |
| Trismus | 1 |
| Gram-Positive Bacterial Infections | 1 |
| Bacterial Infections | 1 |
| Encephalitis, Tick-Borne | 1 |
| Hepatitis A | 1 |
| Epiglottitis | 1 |
| Pneumonia | 1 |
| Gastritis | 1 |
| Stomach Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fire and water damage restoration companies in the United States](https://specstream.ai/data/businesses/fire-and-water-damage-restoration-companies/united-states)
- [European restaurants in the United States](https://specstream.ai/data/businesses/european-restaurants/united-states)
- [Electronic parts suppliers in the United States](https://specstream.ai/data/businesses/electronic-parts-suppliers/united-states)
- [Doner kebab restaurants in the United States](https://specstream.ai/data/businesses/doner-kebab-restaurants/united-states)
- [Customs brokers in the United States](https://specstream.ai/data/businesses/customs-brokers/united-states)
- [Computer hardware companies in the United States](https://specstream.ai/data/businesses/computer-hardware-companies/united-states)
